# Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

> **NCT00290511** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Mitoxantrone
- **DRUG:** Rituximab
- **DRUG:** Zevalin
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00290511
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06-29
- **Primary completion:** 2021-02-12
- **Final completion:** 2021-02-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2022-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290511, "Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00290511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*